Stories often frame the opioid crisis around pills alone: misleading claims by drug makers, too many prescriptions written, growing dependence among users. This account holds up, yet only partly. Missing from view is the backdrop of shared assumptions that allowed such outcomes to unfold. Not born out of nothing, the situation grew slowly. It took root where ideas about discomfort, medical duty, and tolerable hardship had already settled in modern life.
During the 1990s, views on pain within U.S. medical circles began changing, slowly but steadily. Instead of downplaying discomfort, more doctors claimed it had long been ignored without good reason. Fear of dependency, they said, made clinicians reluctant to prescribe strong medications even when needed. Because of this, patients often went without proper care. Around that time, an influential group, the American Pain Society, began pushing a new concept: pain deserved status equal to basic health markers like temperature or pulse. Measuring it regularly became standard advice. Behind the scenes, financial support came from pharmaceutical companies eager to promote their products. One such company, Purdue Pharma, launched OxyContin in 1996 and helped fund campaigns promoting stronger pain treatment. Later found untrue, the claim accompanied promotion of the drug, that its long-acting form supposedly prevented misuse. Prescriptions spread fast among physicians. Blurred lines emerged where evidence ended and persuasion began.
Later years show a clear pattern. As prescriptions rose after the 1990s, so did overdose fatalities. Once controls limited opioid access, reliance shifted. Heroin became common among those affected. Soon after, illegal fentanyl entered widespread use, lower cost, easier to get, far deadlier than what came before. Well into the 2020s, more than 80,000 people in the United States died annually from opioid overdoses. Though the source shifted from prescription medications to illicit substances, the core issue stayed unchanged: individuals suffering, lacking proper care, turning to drugs for comfort.
What if pain avoidance became a cultural norm? Medical anthropology explores this angle when studying historical patterns. Culture shapes responses to suffering, not just medicine. In America, relief often took priority over endurance. Access alone does not explain it; other nations used similar drugs without spiraling. Rates of opioid prescriptions in the U.S. long stood out among wealthy peers. This is not due only to greater physical pain among Americans. Rooted deeper lies a cultural mindset, one treating suffering as an issue demanding resolution. Medicine, within this view, takes on the role of fixer. Enduring distress feels wrong here; it suggests inadequate treatment, not inevitable experience. Such ideas do not appear everywhere equally. Their presence ties closely to particular historical conditions.
Geography plays a role in how the crisis unfolded. Hardest hit were rural areas and towns shaped by industrial decline, regions where factories shut down, taking steady jobs with them, while support networks weakened over many years. Scientists started using the term "deaths of despair" to describe patterns connecting opioid overdoses, suicides, and alcoholic liver damage. Such fatalities did not stem from infection; rather, they came from being left behind economically and emotionally adrift. Though substances caused death, it was society's breakdown that led individuals toward them.
What unfolds during an opioid crisis often mirrors how societies handle distress, through pills rather than deeper change. Who is trusted when speaking of pain shapes whose struggle becomes visible. Access to care, once addiction takes hold, depends heavily on location and skin color. Sympathy arrives late, if at all, for some; for others, it comes swiftly. Years passed while responses to substance dependence in cities and Black neighborhoods leaned toward punishment. Only when suburban and rural white areas were hit did the tone shift from blame to aid. Medical anthropology probes this gap. Same pills. Different results.